Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.

Continuing 5-ASA after escalation to advanced therapy in ulcerative colitis is associated with lower odds of clinical remission.

Background mucosal inflammation at CRC diagnosis is linked to worse recurrence-free and cancer-specific survival in ulcerative colitis.

A research team led by the Medical University of Vienna and the University of Vienna has investigated a possible link between ...

A research team led by the Medical University of Vienna and the University of Vienna has investigated a possible link between ...

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

In tandem with methotrexate, the drug is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ...

Learn about the potential benefits of the Mediterranean diet for managing ulcerative colitis, including lower inflammation and improved gut health, with expert tips.

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...